Stock Events

Stock Events

Intra-Cellular Therapies 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes competes in the psychiatric and neurological disorder treatment space, offering products that directly compete with ITCI's offerings.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
Acadia Pharmaceuticals specializes in CNS disorders, with products that compete in the schizophrenia and mental health treatment market, similar to ITCI.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries has a broad portfolio that includes CNS treatments, competing with ITCI in the generic and branded drug markets for mental health.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products that compete in the mental health and neurodegenerative diseases space, overlapping with ITCI's market.
Novartis
NVS
Mkt Cap292.35B
Novartis offers treatments for neurological conditions, competing with ITCI in research and development of new therapies for CNS disorders.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse portfolio that includes treatments for CNS disorders, competing with ITCI in the development and marketing of drugs for mental health conditions.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a strong focus on neurodegeneration and psychiatric disorders, making it a direct competitor to ITCI in the mental health drug market.
Merck
MRK
Mkt Cap366B
Merck & Co. invests in CNS disorder treatments, including schizophrenia and depression, areas where ITCI is also active.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a portfolio that includes psychiatric drugs, competing with ITCI in the development and commercialization of treatments for mental health disorders.

About

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Show more...
CEO
Dr. Sharon Mates Ph.D.
Employees
860
Country
United States
ISIN
US46116X1019
WKN
000A402CM

Listings

MU
DE
23I.MU

0 Comments

Share your thoughts

FAQ

What is Intra-Cellular Therapies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Intra-Cellular Therapies stocks are traded under the ticker 23I.MU.
How many employees does Intra-Cellular Therapies have?▼
As of September 04, 2026, the company has 860 employees.
In which sector is Intra-Cellular Therapies located?▼
Intra-Cellular Therapies operates in the Health & Wellness sector.
When did Intra-Cellular Therapies complete a stock split?▼
Intra-Cellular Therapies has not had any recent stock splits.
Where is Intra-Cellular Therapies headquartered?▼
Intra-Cellular Therapies is headquartered in Bedminster, United States.